Main Menu


Publications Highlights View all by category

Types of Publications

Journal Articles

Tree, A.C. Ostler, P. van der Voet, H. Chu, W. Loblaw, A. Ford, D. Tolan, S. Jain, S. Martin, A. Staffurth, J. Armstrong, J. Camilleri, P. Kancherla, K. Frew, J. Chan, A. Dayes, I.S. Duffton, A. Brand, D.H. Henderson, D. Morrison, K. Brown, S. Pugh, J. Burnett, S. Mahmud, M. Hinder, V. Naismith, O. Hall, E. van As, N. PACE Trial Investigators,, (2022). Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. , .  show abstract

Brown, S.R. Hinsley, S. Hall, E. Hurt, C. Baird, R.D. Forster, M. Scarsbrook, A.F. Adams, R.A. (2022). A Road Map for Designing Phase I Clinical Trials of Radiotherapy-Novel Agent Combinations. , , p. clincanres.4087.2021.  show abstract

Love, S.B. Cafferty, F. Snowdon, C. Carty, K. Savage, J. Pallmann, P. McParland, L. Brown, L. Masters, L. Schiavone, F. Hague, D. Townsend, S. Amos, C. South, A. Sturgeon, K. Langley, R. Maughan, T. James, N. Hall, E. Kernaghan, S. Bliss, J. Turner, N. Tutt, A. Yap, C. Firth, C. Kong, A. Mehanna, H. Watts, C. Hills, R. Thomas, I. Copland, M. Bell, S. Sebag-Montefiore, D. Jones, R. Parmar, M.K. Sydes, M.R. (2022). Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. , Vol.23 (1), p. 757.  show abstract

Dearnaley, D. Hinder, V. Hijab, A. Horan, G. Srihari, N. Rich, P. Houston, J.G. Henry, A.M. Gibbs, S. Venkitaraman, R. Cruickshank, C. Hassan, S. Miners, A. Mason, M. Pedley, I. Payne, H. Brock, S. Wade, R. Robinson, A. Din, O. Lees, K. Graham, J. Worlding, J. Murray, J. Parker, C. Griffin, C. Sohaib, A. Hall, E. PROMPTS investigators,, (2022). Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. The lancet. oncology, .  show abstract

Hall, E. Hussain, S.A. Porta, N. Lewis, R. Crundwell, M. Jenkins, P. Rawlings, C. Tremlett, J. Sreenivasan, T. Wallace, J. Syndikus, I. Sheehan, D. Lydon, A. Huddart, R. James, N. BC2001 Investigators,, (2022). Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. , , pp. S0302-2838(22)02265.  show abstract

Parr, H. Hall, E. Porta, N. (2022). Joint models for dynamic prediction in localised prostate cancer: a literature review. , .  show abstract

Heer, R. Lewis, R. Vadiveloo, T. Yu, G. Mariappan, P. Cresswell, J. McGrath, J. Nabi, G. Mostafid, H. Lazarowicz, H. Kelly, J. Duncan, A. Penegar, S. Breckons, M. Wilson, L. Clark, E. Feber, A. Orozco-Leal, G. Tandogdu, Z. Taylor, E. N’Dow, J. Norrie, J. Ramsay, C. Rice, S. Vale, L. MacLennan, G. Hall, E. (2022). A Randomized Trial of PHOTOdynamic Surgery in Non–Muscle-Invasive Bladder Cancer. , .

Nutting, C.M. Griffin, C.L. Sanghera, P. Foran, B. Beasley, M. Bernstein, D. Cosgrove, V. Fisher, S. West, C.M. Sibtain, A. Palaniappan, N. Urbano, T.G. Sen, M. Soe, W. Rizwanullah, M. Wood, K. Ramkumar, S. Junor, E. Cook, A. Roques, T. Scrase, C. Bhide, S.A. Gujral, D. Harrington, K.J. Mehanna, H. Miah, A. Emson, M. Gardiner, D. Morden, J.P. Hall, E. ART DECO Trial Management Group,, (2021). Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial. European journal of cancer, Vol.153, pp. 242-256.  show abstract

Mateo, J. Porta, N. Bianchini, D. McGovern, U. Elliott, T. Jones, R. Syndikus, I. Ralph, C. Jain, S. Varughese, M. Parikh, O. Crabb, S. Robinson, A. McLaren, D. Birtle, A. Tanguay, J. Miranda, S. Figueiredo, I. Seed, G. Bertan, C. Flohr, P. Ebbs, B. Rescigno, P. Fowler, G. Ferreira, A. Riisnaes, R. Pereira, R. Curcean, A. Chandler, R. Clarke, M. Gurel, B. Crespo, M. Nava Rodrigues, D. Sandhu, S. Espinasse, A. Chatfield, P. Tunariu, N. Yuan, W. Hall, E. Carreira, S. de Bono, J.S. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The lancet. oncology, Vol.21 (1), pp. 162-174.  show abstract

Birtle, A. Johnson, M. Chester, J. Jones, R. Dolling, D. Bryan, R.T. Harris, C. Winterbottom, A. Blacker, A. Catto, J.W. Chakraborti, P. Donovan, J.L. Elliott, P.A. French, A. Jagdev, S. Jenkins, B. Keeley, F.X. Kockelbergh, R. Powles, T. Wagstaff, J. Wilson, C. Todd, R. Lewis, R. Hall, E. (2020). Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The lancet, Vol.395 (10232), pp. 1268-1277.

Dearnaley, D. Syndikus, I. Mossop, H. Khoo, V. Birtle, A. Bloomfield, D. Graham, J. Kirkbride, P. Logue, J. Malik, Z. Money-Kyrle, J. O'Sullivan, J.M. Panades, M. Parker, C. Patterson, H. Scrase, C. Staffurth, J. Stockdale, A. Tremlett, J. Bidmead, M. Mayles, H. Naismith, O. South, C. Gao, A. Cruickshank, C. Hassan, S. Pugh, J. Griffin, C. Hall, E. CHHiP Investigators,, (2016). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. The lancet. oncology, Vol.17 (8), pp. 1047-1060.  show abstract